SCHEMBL407913

SCHEMBL407913

CN1CCc2[nH]c3ccc(Br)cc3c2C1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.70
BAZ2B Q9UIF8 2/20 0.66
ALOX15 P16050 2/20 0.65
HSD17B10 Q99714 2/20 0.65
USP2 O75604 2/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2D6 P10635 1/20 0.65
CYP2C9 P11712 1/20 0.65
CHRNA7 P36544 1/20 0.64
SIRT2 Q8IXJ6 1/20 0.61
HTR6 P50406 5/20 0.60
MAPT P10636 2/20 0.59
POLB P06746 2/20 0.58
GAA P10253 1/20 0.58
ALDH1A1 P00352 2/20 0.56
MAPK1 P28482 2/20 0.56
KDM4E B2RXH2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27099161 0.88 CHRNA7 (0.64) L3MBTL1BAZ2BALOX15HSD17B10USP2
SCHEMBL12868041 0.86 BAZ2B (0.56) L3MBTL1BAZ2BALOX15HSD17B10USP2
Dehydrostobadine SCHEMBL29468212 0.84 L3MBTL1 (0.97) L3MBTL1BAZ2BALOX15HSD17B10USP2
Dehydrostobadine SCHEMBL167500 0.84 L3MBTL1 (0.97) L3MBTL1BAZ2BALOX15HSD17B10USP2
SCHEMBL2186097 0.82 L3MBTL1 (0.70) L3MBTL1BAZ2BALOX15HSD17B10USP2
SCHEMBL19252850 0.82 L3MBTL1 (0.70) L3MBTL1BAZ2BALOX15HSD17B10USP2
Dehydrostobadine SCHEMBL2837548 0.82 L3MBTL1 (1.00) L3MBTL1BAZ2BALOX15HSD17B10USP2
SCHEMBL3024458 0.82 L3MBTL1 (0.70) L3MBTL1ALOX15HSD17B10USP2CYP1A2
SCHEMBL13356240 0.82 L3MBTL1 (0.70) L3MBTL1ALOX15HSD17B10USP2CYP1A2
SCHEMBL167328 0.82 L3MBTL1 (0.70) L3MBTL1BAZ2BALOX15HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2420235-A1 Methods and combination therapies for treating alzheimer's disease Medivation Neurology, Inc. (US) 2012-02-22 EP claimed
US-20100152108-A1 METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE MEDIVATION NEUROLOGY, INC. (US) 2010-06-17 US claimed
US-20100152225-A1 HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME MEDIVATION NEUROLOGY, INC. 2010-06-17 US claimed
US-20100099700-A1 HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) MEDIVATION NEUROLOGY, INC. 2010-04-22 US claimed
EP-2086538-A2 COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL Medivation Neurology, Inc. (US) 2009-08-12 EP claimed
EP-2063892-A2 METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) Medivation Neurology, Inc. (US) 2009-06-03 EP claimed
WO-2009039420-A9 METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES MEDIVATION NEUROLOGY INC (US) 2009-05-07 WO claimed
WO-2009039420-A1 METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES MEDIVATION NEUROLOGY, INC. (US) 2009-03-26 WO claimed
US-20080234310-A1 Methods and Compositions for Slowing Aging MEDIVATION, INC. 2008-09-25 US claimed
EP-1692131-A4 METHODS AND COMPOSITIONS FOR SLOWING AGING MEDIVATION INC (US) 2008-08-20 EP claimed
WO-2008051599-A2 COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL MEDIVATION NEUROLOGY, INC. (US) 2008-05-02 WO claimed
WO-2008036410-A2 METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) MEDIVATION NEUROLOGY, INC. (US) 2008-03-27 WO claimed
US-20070225316-A1 Methods and compositions for treating schizophrenia MEDIVATION, INC. 2007-09-27 US claimed
US-20070179174-A1 Methods and compositions for slowing aging MEDIVATION, INC. 2007-08-02 US claimed
US-20070117835-A1 Methods and compositions for treating Huntington's disease MEDIVATION NEUROLOGY, INC. 2007-05-24 US claimed
US-20070117834-A1 Methods and compositions for treating Huntington's disease MEDIVATION NEUROLOGY, INC. 2007-05-24 US claimed
WO-2007041697-A2 HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE MEDIVATION, INC. (GB) 2007-04-12 WO claimed
EP-1692131-A2 METHODS AND COMPOSITIONS FOR SLOWING AGING MEDIVATION, INC. (US) 2006-08-23 EP claimed
WO-2005055951-A2 METHODS AND COMPOSITIONS FOR SLOWING AGING MEDIVATION, INC. (US) 2005-06-23 WO claimed
EP-0876818-B1 AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS SELENA PHARMACEUTICALS INC (US) 2002-12-18 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152108-A1 METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE PSEN2, APP, PSEN1 L3MBTL1 4152/4885BAZ2B 589/4885ALOX15 1029/4885
US-20070225316-A1 Methods and compositions for treating schizophrenia SLC6A3, DBH, GRIN3B L3MBTL1 4439/4885BAZ2B 957/4885ALOX15 828/4885
US-20070179174-A1 Methods and compositions for slowing aging PRDX5, HMOX1, SHMT2 L3MBTL1 1438/4885BAZ2B 1574/4885ALOX15 290/4885
US-20070117835-A1 Methods and compositions for treating Huntington's disease HTT, HYPK, HTR6 L3MBTL1 4123/4885BAZ2B 919/4885ALOX15 2543/4885
US-20100152225-A1 HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME HPD, KYNU, IDO1 L3MBTL1 3532/4885BAZ2B 648/4885ALOX15 1441/4885
US-20100099700-A1 HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) HTT, NLN, SMN1; SMN2 L3MBTL1 321/4885BAZ2B 507/4885ALOX15 71/4885
US-20070117834-A1 Methods and compositions for treating Huntington's disease HTT, HYPK, HTR6 L3MBTL1 4123/4885BAZ2B 919/4885ALOX15 2543/4885
US-20080234310-A1 Methods and Compositions for Slowing Aging PRDX5, HMOX1, SHMT2 L3MBTL1 1438/4885BAZ2B 1574/4885ALOX15 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.